Advertisement

Impact of Dopamine Infusion on Renal Function in Hospitalized Heart Failure Patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial

Published:September 06, 2010DOI:https://doi.org/10.1016/j.cardfail.2010.07.246

      Abstract

      Background

      Worsening renal function (WRF) and hypokalemia related to diuretic use for acute decompensated heart failure (ADHF) are common and associated with poor prognosis. Low-dose dopamine infusion improves renal perfusion; its effect on diuresis or renal function specifically in ADHF is not known.

      Methods and Results

      Sixty consecutive ADHF patients (age 75.7 ± 11.2 years; 51.7% female; left ventricular ejection fraction 35.3 ± 12.1%) were randomized, after receiving a 40 mg intravenous furosemide bolus, to either high-dose furosemide (HDF, 20 mg/h continuous infusion for 8 hours) or low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5 μg kg−1 min−1 continuous infusion for 8 hours). Both strategies were compared for total diuresis, WRF (defined as a rise in serum creatinine of >0.3 mg/dL from baseline to 24 hours), electrolyte balance, and 60-day postdischarge outcomes. Mean hourly excreted urine volume (272 ± 149 mL in HDF vs 278 ± 186 mL in LDFD group; P = .965) and changes in dyspnea score (Borg index: −4.4 ± 2.1 in HDF group vs −4.7 ± 2.0 in LDFD group; P = .575) during the 8 hours of protocol treatment were similar in the two groups. WRF was more frequent in the HDF (n = 9; 30%) than in the LDFD group (n = 2; 6.7%; P = .042). Serum potassium changed from 4.3 ± 0.5 to 3.9 ± 0.4 mEq/L at 24 hours (P = .003) in the HDF group and from 4.4 ± 0.5 to 4.2 ± 0.5 mEq/L at 24 hours (P = .07) in the LDFD group. Length of stay and 60-day mortality or rehospitalization rates (all-cause, cardiovascular, and worsening HF) were similar in the two groups.

      Conclusions

      In ADHF patients, the combination of low-dose furosemide and low-dose dopamine is equally effective as high-dose furosemide but associated with improved renal function profile and potassium homeostasis.

      Clinical Trial Registration Information

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ronco C.
        • Haapio M.
        • House A.A.
        • Anavekar N.
        • Bellomo R.
        Cardiorenal syndrome.
        J Am Coll Cardiol. 2008; 52: 1527-1539
        • Akhter M.W.
        • Aronson D.
        • Bitar F.
        • Khan S.
        • Singh H.
        • Singh R.P.
        • et al.
        Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure.
        Am J Cardiol. 2004; 94: 957-960
        • Giamouzis G.
        • Kalogeropoulos A.P.
        • Georgiopoulou V.V.
        • Agha S.A.
        • Rashad M.A.
        • Laskar S.R.
        • et al.
        Incremental value of renal function in risk prediction with the Seattle Heart Failure Model.
        Am Heart J. 2009; 157: 299-305
        • Forman D.E.
        • Butler J.
        • Wang Y.
        • Abraham W.T.
        • O’Connor C.M.
        • Gottlieb S.S.
        • et al.
        Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.
        J Am Coll Cardiol. 2004; 43: 61-67
        • Krumholz H.M.
        • Chen Y.T.
        • Vaccarino V.
        • Wang Y.
        • Radford M.J.
        • Bradford W.D.
        • et al.
        Correlates and impact on outcomes of worsening renal function in patients ≥65 years of age with heart failure.
        Am J Cardiol. 2000; 85: 1110-1113
        • Gottlieb S.S.
        • Abraham W.
        • Butler J.
        • Forman D.E.
        • Loh E.
        • Massie B.M.
        • et al.
        The prognostic importance of different definitions of worsening renal function in congestive heart failure.
        J Card Fail. 2002; 8: 136-141
        • Peacock W.F.
        • Costanzo M.R.
        • De Marco T.
        • Lopatin M.
        • Wynne J.
        • Mills R.M.
        • et al.
        Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry.
        Cardiology. 2009; 113: 12-19
        • Felker G.M.
        • O’Connor C.M.
        • Braunwald E.
        • for the Heart Failure Clinical Research Network I
        Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil?.
        Circ Heart Fail. 2009; 2: 56-62
        • Gottlieb S.S.
        • Brater D.C.
        • Thomas I.
        • Havranek E.
        • Bourge R.
        • Goldman S.
        • et al.
        BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.
        Circulation. 2002; 105: 1348-1353
        • Butler J.
        • Forman D.E.
        • Abraham W.T.
        • Gottlieb S.S.
        • Loh E.
        • Massie B.M.
        • et al.
        Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.
        Am Heart J. 2004; 147: 331-338
        • Ellison D.H.
        Diuretic therapy and resistance in congestive heart failure.
        Cardiology. 2001; 96: 132-143
        • Cooper H.A.
        • Dries D.L.
        • Davis C.E.
        • Shen Y.L.
        • Domanski M.J.
        Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.
        Circulation. 1999; 100: 1311-1315
        • Wang D.J.
        • Dowling T.C.
        • Meadows D.
        • Ayala T.
        • Marshall J.
        • Minshall S.
        • et al.
        Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
        Circulation. 2004; 110: 1620-1625
        • Elkayam U.
        • Bitar F.
        • Akhter M.W.
        • Khan S.
        • Patrus S.
        • Derakhshani M.
        Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations.
        J Cardiovasc Pharmacol Ther. 2004; 9: 227-241
        • Leier C.V.
        • Bambach D.
        • Thompson M.J.
        • Cattaneo S.M.
        • Goldberg R.J.
        • Unverferth D.V.
        Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure.
        Am J Cardiol. 1981; 48: 1115-1123
        • Bayram M.
        • De Luca L.
        • Massie M.B.
        • Gheorghiade M.
        Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
        Am J Cardiol. 2005; 96: 47G-58G
        • Ungar A.
        • Fumagalli S.
        • Marini M.
        • Di Serio C.
        • Tarantini F.
        • Boncinelli L.
        • et al.
        Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure.
        Crit Care Med. 2004; 32: 1125-1129
        • Elkayam U.
        • Ng T.M.
        • Hatamizadeh P.
        • Janmohamed M.
        • Mehra A.
        Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action.
        Circulation. 2008; 117: 200-205
        • Brater D.C.
        Diuretic therapy.
        N Engl J Med. 1998; 339: 387-395
        • Grant S.
        • Aitchison T.
        • Henderson E.
        • Christie J.
        • Zare S.
        • McMurray J.
        • et al.
        A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise.
        Chest. 1999; 116: 1208-1217
        • Smilde T.D.
        • van Veldhuisen D.J.
        • Navis G.
        • Voors A.A.
        • Hillege H.L.
        Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.
        Circulation. 2006; 114: 1572-1580
        • Seri I.
        • Kone B.C.
        • Gullans S.R.
        • Aperia A.
        • Brenner B.M.
        • Ballermann B.J.
        Influence of Na+ intake on dopamine-induced inhibition of renal cortical Na(+)-K(+)-ATPase.
        Am J Physiol. 1990; 258: F52-F60
        • Gildea J.J.
        Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance.
        Curr Opin Nephrol Hypertens. 2009; 18: 28-32
        • Richer M.
        • Robert S.
        • Lebel M.
        Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man.
        Crit Care Med. 1996; 24: 1150-1156
        • Hoogenberg K.
        • Smit A.J.
        • Girbes A.R.
        Effects of low-dose dopamine on renal and systemic hemodynamics during incremental norepinephrine infusion in healthy volunteers.
        Crit Care Med. 1998; 26: 260-265
        • Goldberg L.I.
        • Rajfer S.I.
        Dopamine receptors: applications in clinical cardiology.
        Circulation. 1985; 72: 245-248
        • Triposkiadis F.
        • Karayannis G.
        • Giamouzis G.
        • Skoularigis J.
        • Louridas G.
        • Butler J.
        The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
        J Am Coll Cardiol. 2009; 54: 1747-1762
        • Frankenstein L.
        • Zugck C.
        • Schellberg D.
        • Nelles M.
        • Froehlich H.
        • Katus H.
        • et al.
        Prevalence and prognostic significance of adrenergic escape during chronic beta-blocker therapy in chronic heart failure.
        Eur J Heart Fail. 2009; 11: 178-184
        • Kaya H.
        • Tufan H.
        • Ozdogan M.
        • Arslan G.
        The protective effect of low-dose dopamine on renal functions in hypotensive rats: an experimental study.
        Ulus Travma Acil Cerrahi Derg. 2006; 12: 189-194
        • White D.H.
        • Crawford M.H.
        • O’Rourke R.A.
        Beneficial effects of prolonged low dose dopamine in hospitalized patients with severe refractory heart failure.
        Clin Cardiol. 1979; 2: 135-139
        • Miller R.R.
        • Awan N.A.
        • Joye J.A.
        • Maxwell K.S.
        • DeMaria A.N.
        • Amsterdam E.A.
        • et al.
        Combined dopamine and nitroprusside therapy in congestive heart failure. Greater augmentation of cardiac performance by addition of inotropic stimulation to afterload reduction.
        Circulation. 1977; 55: 881-884
        • Cotter G.
        • Weissgarten J.
        • Metzkor E.
        • Moshkovitz Y.
        • Litinski I.
        • Tavori U.
        • et al.
        Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
        Clin Pharmacol Ther. 1997; 62: 187-193
        • Chan T.Y.
        Low-dose dopamine in severe right heart failure and chronic obstructive pulmonary disease.
        Ann Pharmacother. 1995; 29: 493-496
        • Friedrich J.O.
        • Adhikari N.
        • Herridge M.S.
        • Beyene J.
        Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death.
        Ann Intern Med. 2005; 142: 510-524
        • Lumlertgul D.
        • Keoplung M.
        • Sitprija V.
        • Moollaor P.
        • Suwangool P.
        Furosemide and dopamine in malarial acute renal failure.
        Nephron. 1989; 52: 40-44
        • Niwattayakul K.
        • Sitprija V.
        Leptospiral acute renal failure: effects of dopamine and furosemide.
        Ren Fail. 2007; 29: 159-162
        • Bellomo R.
        • Chapman M.
        • Finfer S.
        • Hickling K.
        • Myburgh J.
        Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial.
        Lancet. 2000; 356: 2139-2143
        • Kellum J.A.
        Use of dopamine in acute renal failure: a meta-analysis.
        Crit Care Med. 2001; 29: 1526-1531
        • Lauschke A.
        • Teichgraber U.K.
        • Frei U.
        • Eckardt K.U.
        “Low-dose” dopamine worsens renal perfusion in patients with acute renal failure.
        Kidney Int. 2006; 69: 1669-1674
        • Lassnigg A.
        • Donner E.
        • Grubhofer G.
        • Presterl E.
        • Druml W.
        • Hiesmayr M.
        Lack of renoprotective effects of dopamine and furosemide during cardiac surgery.
        J Am Soc Nephrol. 2000; 11: 97-104
        • Pitt B.
        • Segal R.
        • Martinez F.A.
        • Meurers G.
        • Cowley A.J.
        • Thomas I.
        • et al.
        Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).
        Lancet. 1997; 349: 747-752
        • Petein M.
        • Heppner B.
        • Bache R.J.
        • Cohn J.N.
        • Pierpont G.L.
        Hemodynamic and regional blood flow response to piroximone (MDL 19,205) in dogs with congestive heart failure: a comparison with dobutamine.
        J Pharmacol Exp Ther. 1987; 241: 956-960
        • Triposkiadis F.
        • Dalampiras P.
        • Kelepeshis G.
        • Skoularigis J.
        • Sitafidis G.
        Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol.
        Int J Clin Pharmacol Ther. 2008; 46: 136-139
        • Ries A.L.
        Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg scale, and visual analog scale.
        COPD. 2005; 2: 105-110
        • Milo-Cotter O.
        • Adams K.F.
        • O’Connor C.M.
        • Uriel N.
        • Kaluski E.
        • Felker G.M.
        • et al.
        Acute heart failure associated with high admission blood pressure—a distinct vascular disorder?.
        Eur J Heart Fail. 2007; 9: 178-183
        • Adams Jr., K.F.
        • Fonarow G.C.
        • Emerman C.L.
        • LeJemtel T.H.
        • Costanzo M.R.
        • Abraham W.T.
        • et al.
        Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).
        Am Heart J. 2005; 149: 209-216